|
169 High Court rejects
claims NICE acted irrationally and unfairly Claims
of unfairness and irrationality in the development of national guidance
on Alzheimer's disease have been rejected by the High Court
PJ 2007;279:169
Full Text
169 10,000 protest online over fee increase More
than 10,000 people have supported an online petition against the proposed
50 per cent increase in Royal Pharmaceutical Society retention fees
PJ 2007;279:169
Full Text
169 Leadership inquiry chairman Nigel
Clarke has been appointed independent chairman of the Royal Pharmaceutical Society's
inquiry on a future professional leadership body
PJ 2007;279:169
Full Text
170 Services for long-term
conditions are improving, but need to be more joined up, says Audit Scotland Services
for people with long-term conditions in Scotland are improving but more needs
to be done to create a joined-up system of care. This is the conclusion of a
report published this week by Audit Scotland
PJ 2007;279:170
Full Text
170 New pre-visit questionnaires for contractors Revision
of the Community Pharmacy Assurance Framework for England has led to the introduction
of a questionnaire that should be completed by pharmacy contractors before they
are visited by primary care trust inspection teams
PJ 2007;279:170
Full Text
170 English contractors must send pricing authority
original CD prescriptions Pharmacy contractors
in England will be required to send original private prescription forms for Controlled
Drugs (form FP10PCD), and not photocopies, to the NHS pricing office from 1 September
2007. The same applies to the equivalent prescriptions originating from Scotland
(PPCD[1]) and Wales (WP10PCD), but dispensed by pharmacies in England
PJ 2007;279:170
Full Text
171 NHS boards to outline
pharmaceutical care services NHS boards in Scotland
are to produce draft pharmaceutical care service (PCS) plans this autumn that
will set out how pharmacy services should be delivered. Details of the plans
are explained in an NHS circular published this week
PJ 2007;279:171
Full Text
171 Scottish Medicines Consortium accepts five
drugs and rejects four in latest appraisals Dopamine
receptor agonist rotigotine (Neupro) is among five drugs accepted for use within
NHS Scotland this week. The Scottish Medicines Consortium rejected a further
four drugs
PJ 2007;279:171
Full Text
171 Incentive payments to be made for ETP in
Scotland Incentive payments are being offered in
Scotland to encourage pharmacists to process prescriptions electronically. The
aim of the payments is to encourage the introduction of the electronic transmission
of prescriptions (ETP)
PJ 2007;279:171
Full Text
172 MHRA asks people what
they think of its plans Consultation has started
on the key challenges and priorities that the Medicines and Healthcare products
Regulatory Agency believes it will face over the next five years
PJ 2007;279:172
Full Text
172 CPW board member provides lifestyle advice
for Eisteddfod festival attendees Richard Evans,
a community pharmacist and Community Pharmacy Wales board member, provided healthy
lifestyle advice to over 60 people at Eisteddfod, the annual Welsh cultural festival,
held in Mold, north-east Wales, last week
PJ 2007;279:172
Full Text
172 Regulatory alliance tells minister how European
law will put patients at risk Risks to patients
introduced by a new European law allowing health professionals to take short-term
work in other countries without being subject to the full rigour of national
regulation have been reported to the Department of Health by the Alliance of
UK Health Regulators on Europe
PJ 2007;279:172
Full Text
172 New service frameworks Competencies
and training frameworks for provision of a smoking cessation service (intermediate
level), supervised consumption of prescribed medicines for substance misusers,
and needle and syringe exchange have been produced by the harmonisation of accreditation
group (HAG)
PJ 2007;279:172
Full Text
172 MeReC Bulletin on arthritis The
August MeReC Bulletin covers issues in rheumatoid arthritis, including the use
of disease modifying drugs, biologic therapies and corticosteroid-induced osteoporosis
PJ 2007;279:172
Full Text
172 Pandemic influenza An
updated summary of the risk of an influenza pandemic originating from an H5N1
virus and the use of antiviral drugs, antibiotics, prepandemic and pandemic vaccines,
has been published by the Department of Health
PJ 2007;279:172
Full Text
172 Waste medicines A
new National Pharmacy Association information leaflet on waste disposal explains
how to comply with the law on accepting, storing, transporting and disposing
of waste medicines
PJ 2007;279:172
Full Text
173 First treatment launched
this week for rare blood disease Treatment for patients with a rare blood disorder — paroxysmal nocturnal haemoglobinuria (PNH) — is now available following the launch of the monoclonal antibody drug eculizumab. Until now PNH patients have received only supportive care
PJ 2007;279:173
Full Text
173 New guidelines on point-of-care testing Updated
recommendations on point-of-care testing have been published by the British Committee
for Standards in Haematology
PJ 2007;279:173
Full Text
174 Interferon beneficial
for patients with suspected MS Patients given interferon
after a neurological episode suggestive of multiple sclerosis (MS) are less likely
to develop clinically definite MS than those given placebo, a three-year follow-up
study has shown
PJ 2007;279:174
Full Text
174 Lumiracoxib withdrawn in Australia due to
safety concerns Lumiracoxib (Prexige), a COX-2
selective inhibitor used for the treatment of osteoarthritis, has been withdrawn
in Australia due to liver-related side effects. Lumiracoxib is licensed in the
UK and a European level review of the evidence in relation to liver reactions
is currently under way. The outcome of the review is expected in September 2007
PJ 2007;279:174
Full Text
174 Thiamine deficiency in diabetics may increase
complications A deficiency in plasma thiamine in
patients with diabetes may increase their risk of developing microvascular complications,
suggest the authors of a small case-control study published online
PJ 2007;279:174
Full Text
174 Leukaemia guidelines published European
guidelines on antimicrobial therapy in patients with acute leukaemia have been
published
PJ 2007;279:174
Full Text
174 Veralipride withdrawal The
European Medicines Agency (EMEA) has recommended the withdrawal of medicines
containing veralipride following a safety review that indicates its side effects
outweigh its limited efficacy
PJ 2007;279:174
Full Text
174 Allergy service scoping survey AAH
Pharmaceuticals is surveying customers and pharmacists about a possible national
allergy testing service
PJ 2007;279:174
Full Text
R&D news
175 Aliskiren and valsartan combination reduces
BP Aliskiren — developed by Novartis — has been shown to reduce blood pressure when used in combination with valsartan better than either agent used alone, according to a study
PJ 2007;279:175
Full Text
175 Plerixafor improves stem cell mobilisation Plerixafor, a novel CXCR4 chemokine antagonist designed to mobilise stem cells for collection, has achieved positive outcomes in two phase III studies of non-Hodgkin's lymphoma and multiple myeloma patients
PJ 2007;279:175
Full Text
175 Therapeutic cancer vaccines could work with
chemotherapy Combining a therapeutic cancer vaccine
with chemotherapy may bring treatment benefits, research on colorectal cancer
patients suggests
PJ 2007;279:175
Full Text
175 Azacitidine shows promise for myelodysplastic
syndromes Two-year survival data for patients taking azacitidine — the first of a new class of agents for myelodysplastic syndromes (where dysfunctioning bone marrow results in the production of malformed or immature blood cells) — have been released by biopharmaceutical company Pharmion
PJ 2007;279:175
Full Text
175 Nanotechnology code of conduct The
European Commission is inviting input for the drafting of a voluntary code of
conduct for research into nanosciences and nanotechnology
PJ 2007;279:175
Full Text
175 NXY-059 shown ineffective Experimental
neuroprotective agent NXY-059 has failed to show efficacy
PJ 2007;279:175
Full Text
175 Animals in research The
Home Office has released the latest statistics on the use of animals in scientific
procedures in Great Britain in 2006
PJ 2007;279:175
Full Text
175 Improving TB immunity Rodents
vaccinated with a tuberculosis strain modified to remove a virulence-associated
gene, have shown greater resistance to tuberculosis infection than those given
standard vaccine
PJ 2007;279:175
Full Text
|
The
Pharmaceutical Journal